Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Oak vs Hims & Hers

Oak
Graded #40

Lower grade

vs+5.099999999999994
Hims & Hers
Graded #36

Higher grade

The verdict

Hims & Hers takes it — 81/100 to 75.9/100.

Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.

We may earn a commission if you start care through some of these links, at no extra cost to you. Affiliate partners are listed first — a capped 3-point edge in board order only. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOak +14
96
82
Dose & formulationHims & Hers +16
62
78
Clinical oversightHims & Hers +16
66
82
Labs & monitoringHims & Hers +22
58
80
FulfillmentOak +4
88
84
Contract termsOak +8
88
80
Oak · left barHims & Hers · right bar

The numbers

MetricOakHims & Hers
WeighScore75.9/10081/100
GradeCB−
Scorecard rank#40#36
SemaglutideFrom $119/mo$199/mo
TirzepatideFrom $185/moNot disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Oak

Graded #40 · C

Strengths

  • Lowest published prices here — semaglutide from $119/mo, tirzepatide from $185/mo
  • One price across every dosage, so titrating up costs no more
  • No membership or subscription fee, and free shipping
  • All 50 states, offered in Spanish as well as English

Where it loses points

  • Same-day approval with no video call means very little clinical contact before a prescription
  • No published lab or monitoring programme
  • Injection only, and no brand-name lane
  • Sold as packages, so re-ordering is on you
Hims & Hers

Graded #36 · B−

Strengths

  • Nationwide
  • Polished app
  • Strong brand trust

Where it loses points

  • Tirzepatide pricing inconsistently disclosed
  • Industry-wide compounding scrutiny

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 43 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard